Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nucleozin SCHEMBL1225006 | 1.00 | NPC1 (0.61) | NPC1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL12691832 | 0.93 | NPC1 (0.63) | NPC1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL1226271 | 0.92 | ALDH1A1 (0.54) | NPC1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL2388044 | 0.91 | ALDH1A1 (0.52) | NPC1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL15391486 | 0.91 | PHGDH (0.52) | NPC1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL899570 | 0.90 | LMNA (0.67) | NPC1ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL898997 | 0.89 | LMNA (0.58) | NPC1ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL899632 | 0.88 | LMNA (0.57) | NPC1ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL10082093 | 0.88 | LMNA (0.57) | ALDH1A1KDM4ESMN1; SMN2HTTUSP2 | |
| SCHEMBL898748 | 0.88 | LMNA (0.57) | ALDH1A1KDM4ESMN1; SMN2HTTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116942832-A | Novel anti-infective strategy for combined infection of influenza virus and staphylococcus aureus | 归属疗法有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116904567-A | Rapid respiratory tract sample detection panel based on nanopore sequencing | 上海市东方医院（同济大学附属东方医院） | 2023-10-20 | — | — | CN | claimed |
| WO-2023036209-A1 | REPLICATION-DEFECTIVE DRUG-RESISTANT INFLUENZA VIRUS AND METHOD FOR DETECTING RECOMBINATION RATE OF NUCLEIC ACID SEGMENT THEREOF | 北京大学 | 2023-03-16 | — | — | WO | claimed |
| EP-4090686-A2 | PRO-ANTIBODY THAT REDUCES OFF-TARGET TOXICITY | Aetio Biotherapy, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | claimed |
| WO-2026047214-A1 | MODULATORS OF THE MITOTIC CELL CYCLE IN CANCER CELLS AND USES THEREOF FOR THE TREATMENT OF CANCER | CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS (DE) | 2026-03-05 | — | — | WO | disclosed |
| EP-4703725-A1 | MODULATORS OF THE MITOTIC CELL CYCLE IN CANCER CELLS AND USES THEREOF FOR THE TREATMENT OF CANCER | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus (DE) | 2026-03-04 | — | — | EP | disclosed |
| EP-4656588-A2 | ENHANCED NANOPARTICLE DELIVERY SYSTEMS | Children's Hospital Medical Center (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-120904125-A | Nucleozin dimer derivative and preparation method and application thereof | 湖南千金湘江药业股份有限公司 | 2025-11-07 | — | — | CN | disclosed |
| CN-120904125-A | Nucleozin dimer derivative and preparation method and application thereof | 湖南千金湘江药业股份有限公司 | 2025-11-07 | — | — | CN | disclosed |
| US-20250340879-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | CHILDRENS HOSPITAL MED CT (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3973960-B1 | NOVEL MEK-INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-114269381-A | Antibodies and methods for treating influenza a infection | 胡默波斯生物医学公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| EP-3973960-A1 | NOVEL MEK-INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | Atriva Therapeutics GmbH (DE) | 2022-03-30 | — | — | EP | disclosed |
| EP-3962530-A1 | ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION | Humabs Biomed SA (CH) | 2022-03-09 | — | — | EP | disclosed |
| CN-109414432-B | Antimicrobial compounds and methods of use thereof | 港大科桥有限公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-3955908-A1 | NOVEL MEK-INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | Atriva Therapeutics GmbH (DE) | 2022-02-23 | — | — | EP | disclosed |
| CN-114007598-A | Novel MEK inhibitors for the treatment of viral and bacterial infections | 归属疗法有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3941464-A1 | RSK INHIBITORS IN THE TREATMENT OF VIRUS DISEASES | Atriva Therapeutics GmbH (DE) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | NPC1 3667/4885ALDH1A1 4386/4885KDM4E 3002/4885 |
| US-20250340879-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | SNRPE, RNASE1, POLRMT | NPC1 46/4885ALDH1A1 3222/4885KDM4E 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.